companies / ambrosrx-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-16 json
| total_raised | 154,000,000154.0M | ○ |
|---|---|---|
| founded | 2024 | |
| hq | 1-10 | |
| industry | unknown | |
| stage | series-a |
Ambros Therapeutics is a clinical-stage biotech advancing neridronate, a non-opioid bisphosphonate, through Phase 3 for complex regional pain syndrome type 1. It serves CRPS-1 patients facing severe unrelenting pain with no FDA-approved drugs available. Backed by RA Capital and Enavate Sciences.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2025-12-01 | series-a | 125,000,000125.0M | null | ○ |
| fact | status | src |
|---|---|---|
| Series A, $125.0M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |